About Cologuard

FEBRUARY 23 - MARCH 1, 2020
Omni Tucson National Resort Tucson, Arizona

Cologuard mascot

Cologuard® is the easy, noninvasive colon cancer screening test you can use at home. It’s the only FDA-approved test that uses stool DNA technology and finds 92% of colon cancers1. Plus, it’s covered by Medicare and most major insurers.  

If you’ve been putting off screening, and you’re 50 years of age or older at average risk for colon cancer, ask your healthcare provider today if this noninvasive option is right for you.

Did you know?

  • Colon cancer is the 2nd leading cause of cancer-related deaths2†
  • When caught in its earliest stages, colorectal cancer is 90% curable3
  • At least 70% of people diagnosed with colorectal cancer have no family

    history4

To learn more, visit CologuardTest.com

 

About Cologuard

Cologuard is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced adenoma (AA) and should be followed by diagnostic colonoscopy. Cologuard is indicated to screen adults of either sex, 50 years or older, who are at typical average-risk for CRC. Cologuard is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high risk individuals.

Cologuard is not for high risk individuals, including those with a history of colorectal cancer and advanced adenoma, a family history of colorectal cancer, IBD or certain hereditary syndromes. Positive Cologuard results should be referred to diagnostic colonoscopy. A negative Cologuard test result does not guarantee absence of cancer or advanced adenoma. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Cologuard performance when used for repeat testing has not been evaluated or established. Rx only.

Statistic is applicable to colorectal cancer

References:

  1. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297.
  2. American Cancer Society. Cancer Statistics Center. American Cancer Society website. https://cancerstatisticscenter.cancer.org/?_ga=2.174638823.450852649.1547649225-2010587624.1541774665#!/ Accessed January 17, 2019. 
  3. National Cancer Institute, Cancer Stat Facts: Colorectal Cancer. National Cancer Institute Website. https://seer.cancer.gov/statfacts/html/colorect.html. Accessed January 3, 2019.
  4. Patel SG, Ahnen DJ. Familial Colon Cancer Syndromes: an Update of a Rapidly Evolving Field. Curr Gastroenterol Rep. 2012;14:428-438.